Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer
Abstract
Most patients with prostate cancer receiving enzalutamide or abiraterone develop resistance. Clinical evidence indicates that serum levels of dehydroepiandrosterone sulfate (DHEAS) and biologically active DHEA remain in the high range despite antiandrogen treatment. The conversion of DHEAS into DHEA by steroid sulfatase (STS) may contribute to sustained intracrine androgen synthesis. Here, we determine the contribution of STS to treatment resistance and explore the potential of targeting STS to overcome resistance in prostate cancer.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 13, 2020
- Source ID
- 10.1158/1078-0432.ccr-20-1682
Entities
People
- Alan P. Lombard
- Allen C Gao
- Cameron M. Armstrong
- Chengfei Liu
- Christopher P Evans
- Jinge Zhao
- Joy C. Yang
- Leandro S. D’Abronzo
- Liangren Liu
- Pui-kai Li
- Ruining Zhao
- Shu Ning
- Wei Lou
Organizations
- Congressionally Directed Medical Research Programs
- National Cancer Institute
- Ohio State University
- United States Department of Veterans Affairs
- University of California
- University of California, Davis